Braeden Lichti discloses 5.01% Bluejay Diagnostics (BJDX) ownership stake

Rhea-AI Filing Summary

Bluejay Diagnostics, Inc. investor ownership has shifted, triggering a Schedule 13G disclosure. Investor Braeden Lichti reports beneficial ownership of 35,500 shares of Bluejay Diagnostics common stock, representing 5.01% of the outstanding shares.

Lichti holds 24,500 shares with sole voting and dispositive power and shares voting and dispositive power over an additional 11,000 shares held through Northstrive Fund II LP. Northstrive Fund II LP itself reports beneficial ownership of 11,000 shares, or 1.55% of the company’s common stock, all with shared voting and dispositive power. These percentages are based on 708,533 shares outstanding as of January 29, 2026.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Bluejay Diagnostics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

095633608

(CUSIP Number)

02/05/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 095633608

1

Names of Reporting Persons

Braeden Lichti

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CANADA (FEDERAL LEVEL)

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 24,500.00
6	Shared Voting Power 11,000.00
7	Sole Dispositive Power 24,500.00
8	Shared Dispositive Power 11,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

35,500.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.01 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Braeden Lichti is, as of the date of this Schedule 13G, the Manager of Northstrive Fund II LP. Percentage ownership is calculated based on 35,500 shares of Bluejay Diagnostics, Inc. ("Issuer") beneficially owned by Mr. Lichti, out of 708,533 shares of the Issuer's issued and outstanding shares of common stock, par value $0.0001 per share ("Common Stock") on January 29, 2026, as reported on the Issuer's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission ("Commission") on January 27, 2026.

SCHEDULE 13G

CUSIP No. 095633608

1

Names of Reporting Persons

Northstrive Fund II LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 11,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 11,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.55 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Braeden Lichti is, as of the date of this Schedule 13G, the Manager of Northstrive Fund II LP. Percentage ownership is calculated based on 11,000 shares beneficially owned by Northstrive Fund II LP, out of 708,533 shares of the Issuer's issued and outstanding shares of Common Stock on January 29, 2026, as reported on the Issuer's Current Report on Form 8-K filed with the Commission on January 27, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Bluejay Diagnostics, Inc.
(b)	Address of issuer's principal executive offices: 360 Massachusetts Avenue, Suite 203, Action, MA 01720
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Braeden Lichti ("Mr. Lichti"); and (ii) Northstrive Fund II LP. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
(b)	Address or principal business office or, if none, residence: 120 Newport Center Drive, Suite 250 Newport Beach, CA 92660
(c)	Citizenship: Mr. Lichti is a citizen of Canada. Northstrive Fund II LP is a Delaware corporation.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 095633608
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Rows 5-11 of the cover page for each Reporting Person and is incorporated herein by reference for each Reporting Person.
(b)	Percent of class: Braeden Lichti: 5.01% Northstrive Fund II LP: 1.55%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Northstrive Fund II LP: 0 Braeden Lichti: 24,500
	(ii) Shared power to vote or to direct the vote: Northstrive Fund II LP: 11,000 Braeden Lichti: 11,000
	(iii) Sole power to dispose or to direct the disposition of: Northstrive Fund II LP: 0 Braeden Lichti: 24,500
	(iv) Shared power to dispose or to direct the disposition of: Northstrive Fund II LP: 11,000 Braeden Lichti: 11,000
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Braeden Lichti

Signature:	/s/ Braeden Lichti
Name/Title:	Braeden Lichti
Date:	02/05/2026

Northstrive Fund II LP

Signature:	/s/ Braeden Lichti
Name/Title:	Braeden Lichti, Manager
Date:	02/05/2026

FAQ

What does the Bluejay Diagnostics (BJDX) Schedule 13G filed by Braeden Lichti report?

The Schedule 13G reports that investor Braeden Lichti beneficially owns 35,500 shares of Bluejay Diagnostics common stock, equal to 5.01% of the company. This includes shares he controls directly and shares over which he shares voting and dispositive power through Northstrive Fund II LP.

How many Bluejay Diagnostics (BJDX) shares does Northstrive Fund II LP own?

Northstrive Fund II LP reports beneficial ownership of 11,000 shares of Bluejay Diagnostics common stock, representing 1.55% of the outstanding shares. All of these shares are reported with shared voting and shared dispositive power, with management authority attributed to Manager Braeden Lichti.

What is the total share count used to calculate ownership percentages for BJDX?

The ownership percentages in the Schedule 13G are calculated using 708,533 shares of Bluejay Diagnostics common stock outstanding as of January 29, 2026. This outstanding share figure comes from a Bluejay Diagnostics Form 8-K, which the reporting persons reference for their percentage calculations.

How is voting power over Bluejay Diagnostics (BJDX) shares allocated for Braeden Lichti?

Braeden Lichti has sole voting and dispositive power over 24,500 shares and shared voting and dispositive power over 11,000 shares. The shared power relates to the 11,000 shares held by Northstrive Fund II LP, where he serves as Manager as of the filing date.

Why did Braeden Lichti and Northstrive Fund II LP file a Schedule 13G for BJDX?

A Schedule 13G is required when an investor exceeds certain beneficial ownership thresholds. Here, Braeden Lichti reports beneficial ownership of 5.01% of Bluejay Diagnostics, with Northstrive Fund II LP reporting 1.55%, prompting this beneficial ownership disclosure under U.S. securities regulations.